BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

Middleton Gary; Yang Yiqun; Campbell Catarina D.; Andre Thierry; Atreya Chloe E.; Schellens Jan H. M.; Yoshino Takayuki; Bendell Johanna C.; Hollebecque Antoine; McRee Autumn J.; Siena Salvatore; Gordon Michael S.; Tabernero Josep; Yaeger Rona; ODwyer Peter J.; De Vos Filip; Van Cutsem Eric; Millholland John M.; Brase Jan C.; Rangwala Fatima; Gasal Eduard; Corcoran Ryan B.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

【24h】

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

机译：BRAF-突变体转录亚型预测结合BRAF，MEK和EGFR障碍的结合BRAF，TRAMETINIB和胰岛素，在结肠直肠癌患者中预测

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The influence of the transcriptional and immunologic context of mutations on therapeutic outcomes with targeted therapy in cancer has not been well defined. BRAF V600E-mutant (BM) colorectal cancer comprises two main transcriptional subtypes, BM1 and BM2. We sought to determine the impact of BM subtype, as well as distinct biological features of those subtypes, on response to BRAF/MEK/EGFR inhibition in patients with colorectal cancer.

机译：目的：对癌症靶向治疗的突变对突变的转录和免疫学背景的影响尚未明确。 BRAF V600E-突变体（BM）结直肠癌包括两个主要转录亚型，BM1和BM2。我们试图确定BM亚型的影响，以及这些亚型的不同生物学特征，响应于结直肠癌患者的BRAF / MEK / EGFR抑制。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2020年第11期|共11页
作者
Middleton Gary; Yang Yiqun; Campbell Catarina D.; Andre Thierry; Atreya Chloe E.; Schellens Jan H. M.; Yoshino Takayuki; Bendell Johanna C.; Hollebecque Antoine; McRee Autumn J.; Siena Salvatore; Gordon Michael S.; Tabernero Josep; Yaeger Rona; ODwyer Peter J.; De Vos Filip; Van Cutsem Eric; Millholland John M.; Brase Jan C.; Rangwala Fatima; Gasal Eduard; Corcoran Ryan B.;
展开▼
作者单位

Univ Birmingham Inst Immunol &

Immunotherapy Birmingham W Midlands England;

Novartis Inst BioMed Res Cambridge MA USA;

Novartis Inst BioMed Res Cambridge MA USA;

Hop St Antoine Paris France;

Univ Calif San Francisco Helen Diller Family Comprehens Canc Ctr San Francisco CA 94143 USA;

Netherlands Canc Inst Amsterdam Netherlands;

Natl Canc Ctr Hosp East Chiba Japan;

Sarah Cannon Res Inst Tennessee Oncol Nashville TN USA;

Inst Gustave Roussy Villejuif France;

Univ N Carolina Chapel Hill NC 27515 USA;

Univ Milan Dept Oncol &

Hematooncol Milan Italy;

Pinnacle Oncol Hematol Scottsdale AZ USA;

Vall dHebron Univ Hosp Barcelona Spain;

Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;

Univ Penn Abramson Canc Ctr Philadelphia PA 19104 USA;

Univ Utrecht Univ Med Ctr Utrecht Dept Med Oncol Utrecht Netherlands;

Univ Hosp Leuven Leuven Belgium;

Novartis Inst BioMed Res Cambridge MA USA;

Novartis Pharma AG Basel Switzerland;

Novartis Pharmaceut E Hanover NJ USA;

Novartis Pharmaceut E Hanover NJ USA;

Massachusetts Gen Hosp Canc Ctr Boston MA 02114 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer [J] . Middleton Gary, Yang Yiqun, Campbell Catarina D., Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第11期

机译：BRAF-突变体转录亚型预测结合BRAF，MEK和EGFR障碍的结合BRAF，TRAMETINIB和胰岛素，在结肠直肠癌患者中预测
2. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. [J] . Ryan B Corcoran, Chloe E Atreya, Gerald S Falchook, Journal of Clinical Oncology . 2015,第34期

机译：结合BRAF和MEK抑制作用与达拉非尼和曲美替尼治疗BRAF V600突变型结直肠癌。
3. Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor [J] . JohnsonD.B., FlahertyK.T., WeberJ.S., Journal of Clinical Oncology . 2014,第33期

机译：BRAFV600突变型黑色素瘤患者单药BRAF抑制剂进展的同时进行BRAF（达巴非尼）和MEK抑制（曲美替尼）
4. Determination of EGFR and VEGF signaling pathway activity by immuno-MALDI to predict the outcome of targeted colorectal cancer (CRC) treatment [C] . Robert Popp, Andrew G. Chambers, Adriana Aguilar-Mahecha, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：免疫马尔迪的EGFR和VEGF信号通路活性预测靶向结直肠癌（CRC）治疗的结果
5. Evaluation of the accuracy of quantitative models in predicting Lynch syndrome (hereditary nonpolyposis colorectal cancer with defective DNA mismatch repair) mutations in a population-based sample of early-onset colorectal cancer patients [D] . Carpiniello, Lauren 2007

机译：在以人群为基础的早发性大肠癌患者样本中预测定量模型预测Lynch综合征（遗传性非息肉病性大肠直肠癌，DNA失配修复缺陷）的准确性
6. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer [O] . Ryan B. Corcoran, Chloe E. Atreya, Gerald S. Falchook, -1

机译：结合BRAF和MEK抑制作用与达拉非尼和曲美替尼治疗BRAF V600 –突变性大肠癌
7. BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer [O] . Gary Middleton, Yiqun Yang, Catarina D. Campbell, 2020

机译：BRAF-突变体转录亚型预测结合BRAF，MEK和EGFR障碍的结合BRAF，TRAMETINIB和胰岛素，在结肠直肠癌患者中预测

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

摘要

著录项

相似文献

相关主题

期刊订阅